Viatris Inc
VTRS
查看详细走势图
14.580USD
+0.240+1.67%
收盘 02/06, 16:00（美东）报价延迟15分钟
16.90B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.67%
5天
+11.38%
1月
+17.58%
6月
+66.63%
今年开始到现在
+17.11%
1年
+33.76%
查看详细走势图
TradingKey Viatris Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Viatris Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名26/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价13.12。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Viatris Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Viatris Inc亮点
亮点风险
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
业绩转亏
公司业绩转亏，最新年度亏损美元
估值合理
公司最新PE估值-4.66，处于3年历史合理位
机构减仓
最新机构持股1.01B股，环比减少4.82%
Mairs and Power 公司持仓
明星投资者Mairs and Power 公司持仓，最新持仓市值10.54K
分析师目标
根据
12
位分析师
买入
评级
13.123
目标均价
-8.48%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Viatris Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Viatris Inc简介
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
公司代码VTRS
公司Viatris Inc
CEOSmith (Scott A)
网址https://www.viatris.com/en
相关品种
